ALZN Stock Overview A clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Alzamend Neuro, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Alzamend Neuro Historical stock prices Current Share Price US$1.20 52 Week High US$15.06 52 Week Low US$1.06 Beta -0.059 1 Month Change -5.14% 3 Month Change -32.20% 1 Year Change -86.52% 3 Year Change -99.58% 5 Year Change n/a Change since IPO -99.94%
Recent News & Updates
Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice Nov 20
Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's Oct 16 Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million. Oct 04
Alzamend Neuro, Inc. announced delayed annual 10-K filing Aug 01 Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding May 10
See more updates
Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice Nov 20
Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's Oct 16 Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million. Oct 04
Alzamend Neuro, Inc. announced delayed annual 10-K filing Aug 01 Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding May 10
Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million. May 08
Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024 May 03
The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024 Mar 31 The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024 Mar 30
Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024 Mar 26
Alzamend Neuro, Inc. announced delayed 10-Q filing Mar 19
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman Jan 06
Price target decreased by 67% to US$20.00 Dec 18
New major risk - Revenue and earnings growth Dec 17
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients Dec 11
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients Nov 21
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Nov 17
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001 Nov 14
New major risk - Market cap size Nov 10
New major risk - Share price stability Nov 04
Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001 Oct 24
Price target increased by 58% to US$6.50 Oct 06
Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients Oct 05
Alzamend Neuro Receives Non-Compliance Notice From Nasdaq Oct 01
Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement Sep 23
New major risk - Negative shareholders equity Sep 14
Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period Aug 08
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans? Jul 26
Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001 Jun 24
Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001 Jun 23
Price target decreased by 41% to US$4.13 Apr 13
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans? Mar 20
Price target decreased to US$7.25 Nov 16
High number of new and inexperienced directors Nov 16
Price target decreased to US$7.25 Nov 02
Alzamend Neuro, Inc. Receives FDA "Study May Proceed" Letter for Phase I/IIa Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type Nov 01
We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate Oct 14
Alzamend Neuro Inc. Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’S Subjects Oct 06
Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial Oct 05
Alzamend Neuro, Inc. Submits Ind Application for Phase I/Iia Trial for an Immunotherapy (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type Sep 30
Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia Sep 29
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement Sep 23
Price target increased to US$15.00 Sep 14
Alzamend Neuro, Inc. Announces CFO Changes Aug 06
Alzamend Neuro Receives Positive Pre-Ind Response from Fda for Al001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder Jul 19
Alzamend Neuro receives positive pre-IND response from FDA for AL001 Jul 18
Alzamend Neuro Receives Non-Compliance Notice from Nasdaq Jun 29
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder May 18
Alzamend Neuro, Inc. Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s May 06
No independent directors Apr 27
Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board Apr 05
Alzamend Neuro Announces Full Data Set from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’S Mar 29
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s Dec 19
Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market Dec 18
Director recently sold US$57k worth of stock Dec 17
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Dec 01
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease Sep 14
Alzamend Neuro Receives Positive Results for Al002 in GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease Jul 25
Alzamend Neuro Submits IND Application for Al001 for Dementia Related to Alzheimer’s Disease Jul 02
Alzamend Neuro closes $14.4M IPO Jun 17
Alzamend Neuro, Inc. has completed an IPO in the amount of $12.5 million. Jun 16 Shareholder Returns ALZN US Biotechs US Market 7D 8.1% 0.7% 0.6% 1Y -86.5% -3.4% 23.8%
See full shareholder returns
Return vs Industry: ALZN underperformed the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: ALZN underperformed the US Market which returned 24.6% over the past year.
Price Volatility Is ALZN's price volatile compared to industry and market? ALZN volatility ALZN Average Weekly Movement 8.3% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ALZN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALZN's weekly volatility has decreased from 29% to 8% over the past year.
About the Company Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.
Show more Alzamend Neuro, Inc. Fundamentals Summary How do Alzamend Neuro's earnings and revenue compare to its market cap? ALZN fundamental statistics Market cap US$6.74m Earnings (TTM ) -US$5.90m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ALZN income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$5.90m Earnings -US$5.90m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 06:07 End of Day Share Price 2024/12/27 00:00 Earnings 2024/10/31 Annual Earnings 2024/04/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alzamend Neuro, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC
Show 0 more analysts 
